Everpar Advisors LLC Invests $371,000 in CVS Health Co. (NYSE:CVS)

Everpar Advisors LLC bought a new stake in CVS Health Co. (NYSE:CVS - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 5,481 shares of the pharmacy operator's stock, valued at approximately $371,000.

Other large investors have also recently bought and sold shares of the company. Whitebox Advisors LLC purchased a new position in shares of CVS Health during the 4th quarter worth $249,000. B&D White Capital Company LLC acquired a new stake in shares of CVS Health during the 4th quarter worth about $417,000. Fairfax Financial Holdings Ltd. Can acquired a new position in CVS Health during the fourth quarter worth approximately $121,742,000. Lazard Asset Management LLC increased its position in CVS Health by 7.3% during the fourth quarter. Lazard Asset Management LLC now owns 4,290,953 shares of the pharmacy operator's stock worth $192,617,000 after buying an additional 293,406 shares during the period. Finally, Seizert Capital Partners LLC grew its stake in shares of CVS Health by 22.8% in the 4th quarter. Seizert Capital Partners LLC now owns 569,527 shares of the pharmacy operator's stock valued at $25,566,000 after purchasing an additional 105,708 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.

Insider Buying and Selling at CVS Health

In other news, Director Guy P. Sansone purchased 1,570 shares of the stock in a transaction on Thursday, June 5th. The stock was purchased at an average price of $63.70 per share, with a total value of $100,009.00. Following the completion of the transaction, the director now owns 12,007 shares in the company, valued at approximately $764,845.90. The trade was a 15.04% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.22% of the stock is owned by company insiders.

CVS Health Trading Up 1.6%

CVS Health stock traded up $1.07 during trading on Friday, hitting $67.42. The company's stock had a trading volume of 7,560,954 shares, compared to its average volume of 10,978,755. The stock has a market capitalization of $85.29 billion, a price-to-earnings ratio of 18.42, a P/E/G ratio of 0.98 and a beta of 0.56. The stock's fifty day moving average is $65.15 and its 200 day moving average is $60.15. CVS Health Co. has a 1-year low of $43.56 and a 1-year high of $72.51. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81.

CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating the consensus estimate of $1.62 by $0.63. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The firm had revenue of $94.59 billion during the quarter, compared to analyst estimates of $93.07 billion. During the same period in the prior year, the firm posted $1.31 earnings per share. The business's quarterly revenue was up 7.0% compared to the same quarter last year. As a group, equities research analysts predict that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 3.95%. The ex-dividend date of this dividend was Tuesday, April 22nd. CVS Health's dividend payout ratio (DPR) is presently 63.48%.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Cowen restated a "buy" rating on shares of CVS Health in a research note on Monday, May 5th. Robert W. Baird lifted their price target on CVS Health from $51.00 to $71.00 and gave the company a "neutral" rating in a research note on Tuesday, April 15th. JPMorgan Chase & Co. lifted their price target on CVS Health from $80.00 to $81.00 and gave the company an "overweight" rating in a research note on Tuesday, February 18th. Argus set a $77.00 price target on CVS Health in a research note on Tuesday, February 18th. Finally, Wells Fargo & Company restated an "overweight" rating and issued a $84.00 price target (up from $76.00) on shares of CVS Health in a research note on Tuesday, May 6th. Two equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $74.75.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.